search
Back to results

Prevention of Adult Caries Study (PACS)

Primary Purpose

Caries, Dental

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
10% w/v chlorhexidine acetate coating FDA IND #45466
Placebo
Sponsored by
Tufts University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Caries, Dental

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 18 years of age and older at least 20 intact natural teeth, excluding third molars 2 or more lesions, of which at least one must be a cavitated D2 or D3 willing and able to provide informed consent Exclusion Criteria pregnant or planning to become pregnant or planning to become pregnant during the study (breastfeeding is permitted) use of fixed orthodontic appliances allergic to any of the ingredients of the study medication long-term antibiotic therapy a history of, or currently active, radiation therapy for cancers of the head or neck Sjögren's syndrome advanced periodontitis consumption of the equivalent of more than five servings of acidic or sugared drinks per day having 10 or more lesions requiring restorative care at the time of the screening visit remineralization therapy within one month of randomization investigator discretion

Sites / Locations

  • Tuba City Regional Health Care
  • Tufts University School of Dental Medicine
  • Dental Services of Massachusetts
  • Center for Health Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo Dental Coating

Active Dental Coating

Arm Description

Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition

10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition

Outcomes

Primary Outcome Measures

Total Net D12FS Caries Increment (Total of Non-cavitated Lesions (D1), Cavitated Lesions (D2) and Sound Surfaces (S))
Study duration was too short to have progression from D2 (cavitated lesions) to D3 (cavitated lesions that involved dentin). D2 and D3 were treated equivalently for analysis. This measure is computed as the sum of weighted counts of transitions in tooth surface status (root and coronal surfaces combined) from randomization to the 13-month follow-up visit. Disease progression had a positive weight (e.g., S-to-D1 (sound to non-cavitated lesion) or D1-to-D2 (non-cavitated to cavitated lesion) = 1, S-to-D2 (sound to cavitated lesion)= 2). Reversal had a negative weight (e.g., D1-to-S = -1). No change, transitions to or from missing or unscorable, and impossible transitions had 0 weight. Incident fillings and crowns were treated the same as incident D2 lesions for purposes of scoring. More details of the transition weights may be found at Vollmer WM et al. (2010). Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a

Secondary Outcome Measures

Cumulative Net D12FS Caries Increment
This measure was computed similar to the total net D12FS increment, but separately scored and combined transitions from the baseline to 7-month visits and from the 7- to 13-month visits, rather than simply looking at the baseline to 13-month visits.
Total Crude D12FS Caries Increment
Computed analogous to the total net D12FS caries increment, but ignoring reversals (essentially assigned them zero weight). Computed only using baseline to 13-month visit data.
Cumulative Crude D12FS Caries Increment
This is computed analogous to the cumulative net D12FS increment, but ignoring reversals by assigning them weights of zero.

Full Information

First Posted
July 26, 2006
Last Updated
May 15, 2017
Sponsor
Tufts University
Collaborators
National Institute of Dental and Craniofacial Research (NIDCR)
search

1. Study Identification

Unique Protocol Identification Number
NCT00357877
Brief Title
Prevention of Adult Caries Study (PACS)
Official Title
Prevention of Adult Caries Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
June 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tufts University
Collaborators
National Institute of Dental and Craniofacial Research (NIDCR)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Adult tooth decay is an infectious disease that afflicts the majority of Americans aged 55 and older and is the most common chronic disease at midlife with an ever growing economic toll. Despite the fact that specific bacteria cause tooth decay, no FDA-approved anti-microbial treatment for decay is available to the American dental professional. The Prevention of Adult Caries Study (PACS) is a study designed to evaluate the efficacy of a topical, temporary, 10% w/v chlorhexidine dental coating in reducing new decay in adult dental patients at risk for decay.
Detailed Description
The Prevention of Adult Caries Study (PACS) is a randomized, double-blind, placebo-controlled Phase III clinical trial conducted under F.D.A. Investigational New Drug license #45,466, with a target enrollment of 1000 at four clinical centers with vastly different populations. The centers participating in this proposed research are: Kaiser Permanente's Dental Plan in Portland, Oregon; Tufts University Dental Clinic in central Boston, Massachusetts; Delta Dental Massachusetts' Dental Clinic in Southborough, Massachusetts; and the dental clinic of the Tuba City Regional Health Care Corporation in Tuba City, Arizona. Kaiser Permanente's Center for Health Research in Portland, Oregon will act as the data-coordinating center, and Tufts University will act as the Administrative Center. This study is designed to evaluate the efficacy of a topical, temporary, 10% w/v chlorhexidine dental coating in reducing caries increment in at-risk adult dental patients. This study will treat participants in months 1(4 weekly applications) and 7(1 application) with final outcome measured at 13 months after randomization. Examiners were trained and certified before data collection started and were recalibrated annually. The primary outcome analysis in the intent -to- treat sample compares active to placebo group on the rank-normalized caries increment score, adjusting for examiner, age and age squared. Multiple imputation (data augmentation using MCMC) will be used to replace missing outcome. Planned secondary analysis examine the secondary caries increment outcomes using the same model, as well as parallel analyses in the per-protocol group. Safety of the coating will be evaluated by comparing development of resistant S. mutans or C. albicans as well as incidence of MedDRA-coded adverse events between the two arms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Caries, Dental

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
983 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo Dental Coating
Arm Type
Placebo Comparator
Arm Description
Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition
Arm Title
Active Dental Coating
Arm Type
Active Comparator
Arm Description
10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition
Intervention Type
Drug
Intervention Name(s)
10% w/v chlorhexidine acetate coating FDA IND #45466
Other Intervention Name(s)
CHX
Intervention Description
Dental coating topically applied by dental professional supragingivally to the full dentition
Intervention Type
Other
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Total Net D12FS Caries Increment (Total of Non-cavitated Lesions (D1), Cavitated Lesions (D2) and Sound Surfaces (S))
Description
Study duration was too short to have progression from D2 (cavitated lesions) to D3 (cavitated lesions that involved dentin). D2 and D3 were treated equivalently for analysis. This measure is computed as the sum of weighted counts of transitions in tooth surface status (root and coronal surfaces combined) from randomization to the 13-month follow-up visit. Disease progression had a positive weight (e.g., S-to-D1 (sound to non-cavitated lesion) or D1-to-D2 (non-cavitated to cavitated lesion) = 1, S-to-D2 (sound to cavitated lesion)= 2). Reversal had a negative weight (e.g., D1-to-S = -1). No change, transitions to or from missing or unscorable, and impossible transitions had 0 weight. Incident fillings and crowns were treated the same as incident D2 lesions for purposes of scoring. More details of the transition weights may be found at Vollmer WM et al. (2010). Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a
Time Frame
(V1) to the 13 month follow-up visit
Secondary Outcome Measure Information:
Title
Cumulative Net D12FS Caries Increment
Description
This measure was computed similar to the total net D12FS increment, but separately scored and combined transitions from the baseline to 7-month visits and from the 7- to 13-month visits, rather than simply looking at the baseline to 13-month visits.
Time Frame
Visit 1, 7-month follow-up, 13-month follow-up
Title
Total Crude D12FS Caries Increment
Description
Computed analogous to the total net D12FS caries increment, but ignoring reversals (essentially assigned them zero weight). Computed only using baseline to 13-month visit data.
Time Frame
V1-13-month follow-up
Title
Cumulative Crude D12FS Caries Increment
Description
This is computed analogous to the cumulative net D12FS increment, but ignoring reversals by assigning them weights of zero.
Time Frame
Visit 1, 7-month follow-up, 13-month follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age and older at least 20 intact natural teeth, excluding third molars 2 or more lesions, of which at least one must be a cavitated D2 or D3 willing and able to provide informed consent Exclusion Criteria pregnant or planning to become pregnant or planning to become pregnant during the study (breastfeeding is permitted) use of fixed orthodontic appliances allergic to any of the ingredients of the study medication long-term antibiotic therapy a history of, or currently active, radiation therapy for cancers of the head or neck Sjögren's syndrome advanced periodontitis consumption of the equivalent of more than five servings of acidic or sugared drinks per day having 10 or more lesions requiring restorative care at the time of the screening visit remineralization therapy within one month of randomization investigator discretion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Athena Papas, PhD DMD
Organizational Affiliation
Tufts University of Dental Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tuba City Regional Health Care
City
Tuba City
State/Province
Arizona
ZIP/Postal Code
86045-0600
Country
United States
Facility Name
Tufts University School of Dental Medicine
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
Facility Name
Dental Services of Massachusetts
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02129
Country
United States
Facility Name
Center for Health Research
City
Portland
State/Province
Oregon
ZIP/Postal Code
97227
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22156917
Citation
Papas AS, Vollmer WM, Gullion CM, Bader J, Laws R, Fellows J, Hollis JF, Maupome G, Singh ML, Snyder J, Blanchard P; PACS Collaborative Group. Efficacy of chlorhexidine varnish for the prevention of adult caries: a randomized trial. J Dent Res. 2012 Feb;91(2):150-5. doi: 10.1177/0022034511424154. Epub 2011 Dec 7.
Results Reference
result
PubMed Identifier
23834229
Citation
Singh M, Papas A, Vollmer W, Bader J, Laws R, Maupome G, Snyder J, Blanchard P. Predictors of coronal caries progression in adults: results from the Prevention of Adult Caries Study. Community Dent Oral Epidemiol. 2013 Dec;41(6):558-64. doi: 10.1111/cdoe.12059. Epub 2013 Jul 9.
Results Reference
derived
PubMed Identifier
22320292
Citation
Banting DW, Amaechi BT, Bader JD, Blanchard P, Gilbert GH, Gullion CM, Holland JC, Makhija SK, Papas A, Ritter AV, Singh ML, Vollmer WM. Examiner training and reliability in two randomized clinical trials of adult dental caries. J Public Health Dent. 2011 Fall;71(4):335-44. doi: 10.1111/j.1752-7325.2011.00278.x. Epub 2011 Aug 17.
Results Reference
derived
PubMed Identifier
20923557
Citation
Vollmer WM, Papas AS, Bader JD, Maupome G, Gullion CM, Hollis JF, Snyder JJ, Fellows JL, Laws RL, White BA; PACS Collaborative Research Group. Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a chlorhexidine dental coating for the prevention of adult caries. BMC Oral Health. 2010 Oct 5;10:23. doi: 10.1186/1472-6831-10-23.
Results Reference
derived

Learn more about this trial

Prevention of Adult Caries Study (PACS)

We'll reach out to this number within 24 hrs